Evaluation of the Effectiveness of Direct-Acting Antiviral Agents in Patients With Hepatitis C

Ozturk-Cerik H., Esen S., ALTINTAŞ ÖNER B., Celik M., Ozdemir T., TANYEL E.

KLIMIK JOURNAL, vol.33, no.3, pp.297-306, 2020 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 33 Issue: 3
  • Publication Date: 2020
  • Doi Number: 10.5152/kd.2020.60
  • Journal Name: KLIMIK JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, Veterinary Science Database
  • Page Numbers: pp.297-306
  • Keywords: Hepatitis C, sofosbuvir, ledipasvir, ombitasvir, paritaprevir, dasabuvir, VIRUS GENOTYPE 1, 4 INFECTION, RIBAVIRIN, EFFICACY, LEDIPASVIR/SOFOSBUVIR, SOFOSBUVIR, SAFETY
  • Eskisehir Osmangazi University Affiliated: Yes


Objective: Hepatitis C virus (HCV) infection is a global problem with personal, social and economic impacts. Approximately 85% of patients infected with HCV cannot achieve virus clearance. Cirrhosis, hepatocellular carcinoma and death may develop in patients with chronic infection.Until recently, treatments for chronic hepatitis C were difficult to use with many side effects, low treatment responses, and relapses. Direct-acting antivirals (DAAs) prevent HCV replication, and thir effectiveness is over 90%. In this study, we aimed to evaluate the achievement of these treatments.